The DOCK2 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to ablate DOCK2 expression in the human 143B osteosarcoma cell line. This gene-disrupted model serves as a powerful tool for investigating DOCK2-dependent signaling and cellular processes under loss-of-function conditions. The polyclonal format provides a heterogeneous mixture of knockout variants, enabling robust population-level analyses without bias from single-clone artifacts.
The 143B cell line is derived from a human bone osteosarcoma and exhibits a fibroblast morphology characteristic of its mesenchymal origin. Widely utilized for mitochondrial studies, 143B cells offer a robust host system for dissecting pathways that intersect with metabolic and cytoskeletal regulation. Their adherent growth and well-characterized signaling networks make them suitable for a range of functional assays.
DOCK2 is a guanine nucleotide exchange factor (GEF) specifically activating the small GTPases Rac1 and Rac2. It functions as a critical link between transmembrane receptor signals and actin cytoskeleton remodeling. Activated by chemokine receptors (e.g., CXCR4, CCR7) and the T cell receptor, DOCK2 forms a complex with ELMO to catalyze Rac-GTP loading. Downstream, Rac-GTP engages the WAVE complex and Arp2/3 to drive actin polymerization, thereby regulating cell migration, adhesion, and immunological synapse formation. The DOCK2/ELMO/Rac axis is further modulated by CRK adaptor proteins, positioning DOCK2 at the nexus of chemokine and Rho GTPase signaling.
In the 143B osteosarcoma model, DOCK2 knockout disrupts Rac-dependent actin dynamics, providing a relevant context for studying mechanisms of tumor cell migration and invasion. Although DOCK2 is prominently linked to hematopoietic cell function, its expression and activity in mesenchymal-derived cells like 143B offer insights into cancer metastasis and cytoskeletal reorganization independent of immune cell-specific pathways. This knockout model thus enables dissection of DOCK2’s non-hematopoietic roles within a cancer biology framework.
Researchers can employ this polyclonal knockout cell population in a variety of assays, including chemotaxis assays to assess directed migration, actin polymerization assays using phalloidin staining, and immunoblotting for active Rac. Flow cytometry and immunofluorescence microscopy allow quantitative assessment of adhesion molecule expression and cytoskeletal architecture. The model is also suited for co-culture experiments to explore tumor-immune interactions. Potential applications span immunology, chemotaxis studies, cytoskeletal dynamics, cancer immunology, and hematopoietic cell migration. For further information on assay conditions, please contact Ascent Research.
